IIB 

115TH CONGRESS 

2D SESSION H. R. 1660 

IN THE SENATE OF THE UNITED STATES 

JANUARY 19, 2018 

Received; read twice and referred to the Committee on Foreign Relations 

AN ACT 

To direct the Administrator of the United States Agency 

for International Development to submit to Congress a 

report on the development and use of global health innovations in the programs, projects, and activities of the 

Agency. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


SSpencer on DSKBBXCHB2PROD with BILLS
2 

HR 1660 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Global Health Innova3 tion Act of 2017’’. 

4 SEC. 2. ANNUAL REPORT. 

5 (a) IN GENERAL.—Not later than 180 days after the 

6 date of the enactment of this Act, and annually thereafter 

7 for a period of 4 years, the Administrator of the United 

8 States Agency for International Development shall submit 

9 to Congress a report on the development and use of global 

10 health innovations in the programs, projects, and activities 

11 of the Agency. 

12 (b) MATTERS TO BE INCLUDED.—The report re13 quired by subsection (a) shall include the following: 

14 (1) A description of— 

15 (A) the extent to which global health inno16 vations described in subsection (a) include 

17 drugs, diagnostics, devices, vaccines, electronic 

18 and mobile health technologies, and related be19 havior change and service delivery innovations; 

20 (B) how innovation has advanced the 

21 Agency’s commitments to achieving an HIV/ 

22 AIDS-free generation, ending preventable child 

23 and maternal deaths, and protecting commu24 nities from infectious diseases, as well as 

25 furthered by the Global Health Strategic 

26 Framework; 


SSpencer on DSKBBXCHB2PROD with BILLS
3 

HR 1660 RFS

1 (C) how goals are set for health product 

2 development in relation to the Agency’s health3 related goals and how progress and impact are 

4 measured towards those goals; 

5 (D) how the Agency’s investments in inno6 vation relate to its stated goals; and 

7 (E) progress made towards health product 

8 development goals. 

9 (2) How the Agency, both independently and 

10 with partners, donors, and public-private partner11 ships, is— 

12 (A) leveraging United States investments 

13 to achieve greater impact in health innovation; 

14 (B) engaging in activities to develop, ad15 vance, and introduce affordable, available, and 

16 appropriate global health products; and 

17 (C) scaling up appropriate health innova18 tions in the development pipeline. 

19 (3) A description of collaboration and coordina20 tion with other Federal departments and agencies, 

21 including the Centers for Disease Control and Pre22 vention, in support of global health product develop23 ment, including a description of how the Agency is 

24 working to ensure critical gaps in product develop25 ment for global health are being filled. 


SSpencer on DSKBBXCHB2PROD with BILLS
4 

HR 1660 RFS

1 (4) A description of how the Agency is coordi2 nating and aligning global health innovation activi3 ties between the Global Development Lab, the Cen4 ter for Accelerating Innovation and Impact, and the 

5 Bureau for Global Health. 

Passed the House of Representatives January 18, 

2018. 

Attest: KAREN L. HAAS, 

Clerk. 


SSpencer on DSKBBXCHB2PROD with BILLS